Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia · 2012 · 3.9K citations · Full text

Medicine, Endocrinology, Internal Medicine +13

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

Ele Ferrannini, Silvia Ramos, Afshin Salsali et al. · Diabetes Care · 2010 · 712 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim et al. · Diabetes Obesity and Metabolism · 2012 · 611 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 603 citations

Medicine, Pharmacokinetics, Pharmacology +17

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

Guntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock et al. · Diabetes Care · 2013 · 479 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15